参考文献/References:
[1] HINKSON A,LALLY H,GIBSON H,et al.Meta-analysis:Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases[J].Aliment Pharmacol Ther,2023,57(7):750-762.
[2] FRIEDMAN S L,PINZANI M.Hepatic fibrosis 2022:Unmet needs and a blueprint for the future[J].Hepatology,2022,75(2):473-488.
[3] ZHANG X,ZENG Y,ZHAO L,et al.Targeting hepatic stellate cell death to reverse hepatic fibrosis[J].Curr Drug Targets,2023,24(7):568-583.
[4] PEISELER M,SCHWABE R,HAMPE J,et al.Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits[J].J Hepatology,2022,77(4):1136-1160.
[5] GONG X,SHAN L,CAO S,et al.Notoginsenoside R1,an active compound from panax notoginseng,inhibits hepatic stellate cell activation and liver fibrosis via MAPK signaling pathway[J].Am J Chin Med,2022,50(2):511-523.
[6] ZHANG Q,QU Y,ZHANG Q,et al.Exosomes derived from hepatitis B virus-infected hepatocytes promote liver fibrosis via miR-222/TFRC axis[J].Cell Biol Toxicol,2023,39(2):467-481.
[7] CHO S S,YANG J H,LEE J H,et al.Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis[J].Free Radic Biol Med,2022,193(2):620-637.
[8] 余思邈,李萍,李园,等.从“见肝之病,知肝传脾,当先实脾”探讨肝硬化的防治[J].北京中医药大学学报,2022,45(1):29-33.
[9] 莫万灵,禄保平,周志文.基于肠道菌群探讨“肝病实脾”法治疗非酒精性脂肪性肝病[J].中医学报,2022,37(3):541-546.
[10] 陈斌,徐嘉蔚,彭杰,等.基于逍遥散及其拆方研究“肝病实脾法”对肝纤维化大鼠肠道菌群的影响[J].临床肝胆病杂志,2016,32(4):657-662.
[11] 车艳玲,宋美琪,徐皓煊,等.基于SWE技术评估三甲逍遥散治疗肝纤维化的临床观察[J].中医药学报,2021,49(2):71-74.
[12] 王奎淞,张秋菊,魏书瑶,等.舒肝和络醒脾方对肝纤维化模型大鼠肝组织Wnt/β-Catenin信号通路的影响[J].临床肝胆病杂志,2022,38(10):2265-2272.
[13] HAMMERICH L,TACKE F.Hepatic inflammatory responses in liver fibrosis[J].Nat Rev Gastroenterol Hepatol,2023,20(10):633-646.
[14] YANG X,LI Q,LIU W,et al.Mesenchymal stromal cells in hepatic fibrosis/cirrhosis:From pathogenesis to treatment[J].Cell Mol Immunol,2023,20(6):583-599.
[15] HAO Y,SONG K,TAN X,et al.Reactive oxygen species-responsive polypeptide drug delivery system targeted activated hepatic stellate cells to ameliorate liver fibrosis[J].ACS Nano,2022,16(12):20739-20757.
[16] 黄进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,42(2):225-227.
[17] 吴迪,谢春娥,李峰,等.基于肠-肝轴探讨茵陈苓桂剂对非酒精性脂肪性肝病大鼠肠黏膜屏障的作用研究[J].现代中西医结合杂志,2021,30(6):571-577.
[18] 蒋俊娥,王振常,陈丹丹,等.王振常治疗肝硬化的经验浅析[J].辽宁中医杂志,2021,48(8):36-38.
[19] 余学竟,赖国权,韦翠,等.基于网络大数据研究逍遥散治疗肝纤维化的作用机制[J].中华中医药学刊,2021,(1):110-114.
[20] 张文超,葛冰景,周薏,等.逍遥散对四氯化碳诱导的急性肝损伤的保护作用及其机制[J].现代中西医结合杂志,2022,31(7):899-936.
[21] YI J,WU S,TAN S,et al.Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis[J].Cell Death Discov,2021,7(1):374-389.
[22] RHO H,TERRY A R,CHRONIS C,et al.Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis[J].Cell Metab,2023,35(8):1406-1423.
[23] LIU G,WEI C,YUAN S,et al.Wogonoside attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis through SOCS1/P53/SLC7A11 pathway[J].Phytother Res,2022,36(11):4230-4243.
[24] WANG C,SU Z,XU J H,et al.Danshensu attenuated lipopolysaccharide-induced LX-2 and T6 cells activation through regulation of ferroptosis[J].Food Sci Nutr,2022,11(1):344-349.
[25] QUE R,CAO M,DAI Y,et al.Decursin ameliorates carbon-tetrachloride-induced liver fibrosis by facilitating ferroptosis of hepatic stellate cells[J].Biochem Cell Biol,2022,100(5):378-386.
相似文献/References:
[1]邱 勇.桃红四物汤对CCl4诱导肝纤维化小鼠治疗作用及其机制研究[J].陕西中医,2019,(12):1673.
QIU Yong..Protective effects of Taohong Siwu decoction on CCl4induced hepatic fibrosis model mice[J].,2019,(2):1673.
[2]周 翔,顾 达,童 聪,等.鳖甲煎丸对CCl4诱导小鼠肝纤维化的治疗作用机制研究[J].陕西中医,2022,(2):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
ZHOU Xiang,GU Da,TONG Cong,et al.Therapeutic mechanism of Biejiajian pills on mice model of liver fibrosis induced by CCl4[J].,2022,(2):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
[3]梁瀞云,唐 燕,司马玲,等.柴胡疏肝散在肝脏疾病中的应用研究进展[J].陕西中医,2022,(11):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
LIANG Jingyun,TANG Yan,SIMA ling,et al.Application of Chihu Shugan powder in liver diseases[J].,2022,(2):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
[4]牛丽娜,窦 婧,马 燕,等.和血柔肝方通过PI3K/Akt/NF-κB信号通路调控自噬相关蛋白改善大鼠肝纤维化机制研究[J].陕西中医,2024,(2):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]
NIU Lina,DOU Jing,MA Yan,et al.Mechanism of Hexue Rougan decoction in relieve liver fibrosis in rats by regulating autophagy-related proteins through PI3K/Akt/NF-κB signaling pathway[J].,2024,(2):165.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.004]
[5]俞佳雯,周 薏,林天龙(加拿大),等.乙肝肝纤维化中西医研究进展[J].陕西中医,2025,46(2):273.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]
YU Jiawen,ZHOU Yi,LIN Tianlong,et al.Progress of traditional Chinese and Western medicine research on chronic hepatitis B hepatic fibrosis[J].,2025,46(2):273.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.027]